HTML Microdata document

This HTML5 document contains 75 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n10	http://www.rxlist.com/cgi/generic3/
n20	http://linked.opendata.cz/resource/drugbank/drug/DB01170/identifier/national-drug-code-directory/
n2	http://linked.opendata.cz/resource/drugbank/drug/
dcterms	http://purl.org/dc/terms/
n16	http://linked.opendata.cz/resource/AHFS/
foaf	http://xmlns.com/foaf/0.1/
n22	http://linked.opendata.cz/resource/drugbank/company/
n8	http://linked.opendata.cz/resource/mesh/concept/
n25	http://linked.opendata.cz/resource/drugbank/drug/DB01170/identifier/chemspider/
n24	http://linked.opendata.cz/resource/drugbank/drug/DB01170/identifier/chebi/
n6	http://bio2rdf.org/drugbank:
n27	http://linked.opendata.cz/resource/drugbank/drug/DB01170/identifier/wikipedia/
n26	http://linked.opendata.cz/resource/drugbank/drug/DB01170/identifier/pharmgkb/
adms	http://www.w3.org/ns/adms#
n11	http://www.drugs.com/mtm/
n28	http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n18	http://linked.opendata.cz/resource/drugbank/drug/DB01170/identifier/pubchem-compound/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n14	http://linked.opendata.cz/resource/drugbank/medicinal-product/
owl	http://www.w3.org/2002/07/owl#
n7	http://linked.opendata.cz/ontology/mesh/
n3	http://linked.opendata.cz/ontology/drugbank/
n19	http://linked.opendata.cz/resource/drugbank/drug/DB01170/identifier/pubchem-substance/
n23	http://linked.opendata.cz/resource/drugbank/drug/DB01170/identifier/kegg-drug/
n4	http://linked.opendata.cz/resource/drugbank/property/
n21	http://linked.opendata.cz/resource/drugbank/drug/DB01170/identifier/drugbank/
xsdh	http://www.w3.org/2001/XMLSchema#
n13	http://linked.opendata.cz/resource/atc/
n12	http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item: n2:DB01170
rdf:type: n3:Drug
n3:description: An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues. [PubChem]
n3:group: approved
n3:halfLife: 1.5 days
n3:indication: For the treatment of moderate and severe hypertension, either alone or as an adjunct, and for the treatment of renal hypertension.
owl:sameAs: n6:DB01170 n28:DB01170
dcterms:title: Guanethidine
adms:identifier: n18:3518 n19:46507567 n20:0083-0049-30 n21:DB01170 n23:D02237 n24:5557 n25:3398 n26:PA449823 n27:Guanethidine
n3:mechanismOfAction: Guanethidine acts at the sympathetic neuroeffector junction by inhibiting or interfering with the release and/or distribution of norepinephrine, rather than acting at the effector cell by inhibiting the association of norepinephrine with its receptors. It is taken up by norepinephrine transporters. It becomes concentrated in NE transmitter vesicles, replacing NE in these vesicles. This leads to a gradual depletion of NE stores in the nerve endings. Once inside the terminal it blocks the release of noradrenaline in response to arrival of an action potential. In contrast to ganglionic blocking agents, Guanethidine suppresses equally the responses mediated by alpha-and beta-adrenergic receptors but does not produce parasympathetic blockade. Since sympathetic blockade results in modest decreases in peripheral resistance and cardiac output, Guanethidine lowers blood pressure in the supine position. It further reduces blood pressure by decreasing the degree of vasoconstriction that normally results from reflex sympathetic nervous activity upon assumption of the upright posture, thus reducing venous return and cardiac output more.
n3:packager: n22:271B4DC8-363D-11E5-9242-09173F13E4C5 n22:271B4DC9-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination: Ismelin is converted by the liver to three metabolites, which are excreted in the urine.
n3:synonym: 2-(1-N,N-Heptamethyleneimino)ethylguanidine Guanidine, (2-(hexahydro-1(2H)-azocinyl)ethyl)- N-(2-Perhydroazocin-1-ylethyl)guanidine (2-(Octahydro-1-azocinyl)ethyl)guanidine Guanetidina Heptamethylenimine, 1-(2-guanidinoethyl)- Guanethidinum Guanethidine Azocine, 1-(2-guanidinoethyl)octahydro- 2-(1'-Azacyclooctyl)ethylguanidine
n3:toxicity: Side effects include drowsiness, dizziness, tiredness or confusion. LD<sub>50</sub>=1000 mg/kg (mouse, oral)
n12:hasAHFSCode: n16:24-08-32
n3:foodInteraction: Take without regard to meals.
n3:salt
n3:synthesisReference: U.S. Patent 2,928,829 U.S. Patent 3,006,913 U.S. Patent 3,055,882
n7:hasConcept: n8:M0009675
foaf:page: n10:guanethidine.htm n11:guanethidine.html
n3:IUPAC-Name: n4:271B4DCF-363D-11E5-9242-09173F13E4C5
n3:InChI: n4:271B4DD5-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula: n4:271B4DD4-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight: n4:271B4DD1-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight: n4:271B4DD2-363D-11E5-9242-09173F13E4C5
n3:SMILES: n4:271B4DD3-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility: n4:271B4DE4-363D-11E5-9242-09173F13E4C5 n4:271B4DCD-363D-11E5-9242-09173F13E4C5
n3:logP: n4:271B4DCE-363D-11E5-9242-09173F13E4C5 n4:271B4DE6-363D-11E5-9242-09173F13E4C5 n4:271B4DCB-363D-11E5-9242-09173F13E4C5
n3:logS: n4:271B4DCC-363D-11E5-9242-09173F13E4C5
n12:hasATCCode: n13:S01EX01 n13:C02CC02
n3:H-Bond-Acceptor-Count: n4:271B4DDB-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count: n4:271B4DDC-363D-11E5-9242-09173F13E4C5
n3:InChIKey: n4:271B4DD6-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-: n4:271B4DD7-363D-11E5-9242-09173F13E4C5
n3:Polarizability: n4:271B4DD9-363D-11E5-9242-09173F13E4C5
n3:Refractivity: n4:271B4DD8-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count: n4:271B4DDA-363D-11E5-9242-09173F13E4C5
n3:absorption: 3-30% of oral dose (poor and highly variable)
n3:affectedOrganism: Humans and other mammals
n3:casRegistryNumber: 645-43-2
n3:category
n3:clearance: * Renal cl=56 ml/min
n3:containedIn: n14:271B4DCA-363D-11E5-9242-09173F13E4C5
n3:Bioavailability: n4:271B4DE0-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter: n4:271B4DE2-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule: n4:271B4DE3-363D-11E5-9242-09173F13E4C5
n3:Melting-Point: n4:271B4DE5-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings: n4:271B4DDF-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge: n4:271B4DDE-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five: n4:271B4DE1-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name: n4:271B4DD0-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-: n4:271B4DDD-363D-11E5-9242-09173F13E4C5